ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptive Biotechnologies Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$23.95−0.07 (-0.29%)
Close on Oct 19, 2026
- Market cap
- $3.83B
- P/E (TTM)
- –
- Dividend yield
- –
Adaptive Biotechnologies Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRD | $212.33M | $145.53M | $102.74M | $87.14M | – | – | – | – | – | 76.7% | +45.9% |
| Immune Medicine | $64.64M | $33.43M | $67.54M | $98.16M | – | – | – | – | – | 23.3% | +93.4% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Immune Medicine Service Revenue | $41.30M | $13.50M | $42.60M | $62.80M | – | – | – | – | – | 14.9% | +205.9% |
| Development Revenue | – | – | – | – | $75.45M | $56.94M | $41.55M | $22.69M | $15.69M | – | – |
| Sequencing Revenue | – | – | – | – | $78.90M | $41.44M | $43.52M | $32.98M | $22.76M | – | – |
| Development Support Revenue | – | – | – | – | $65.45M | $54.44M | $39.55M | $12.69M | $15.69M | – | – |
| Development Revenue Regulatory Milestones | – | – | – | – | $10.00M | $2.50M | $2.00M | $10.00M | – | – | – |
| Sequencing Revenue From Coverage Policy | – | – | – | – | – | – | $1.60M | – | – | – | – |
| Sequencing Revenue From Test Deliver | – | – | – | – | – | – | $400.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Adaptive Biotechnologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.